Healthcare Finance >>>
Kinetic Concepts plans to buy back $112 million of bonds due 2019 when it has excess cash provided that the debt trades at an attractive price, said Nathan Speicher, the issuer’s vice president of investor relations and treasury. Click HERE for more.
Contribution by Phil Birch, Ph.D., Senior Vice President, Global Strategic Marketing at Aptiv Solutions Adaptive designs can bring substantial benefits to sponsor companies if adopted broadly at the portfolio level. For instance, available data indicate that futility stopping in Phase II and Phase III can save mid-size biopharma companies between $5 million and $10 [...]
by Andrew Berens, Grace Guo, Bloomberg Industries AbbVie’s supplemental Biologics License Application (sBLA) to expand Humira’s existing approval for ankylosing spondylitis to include the treatment of non-radiographic axial spondyloarthritis has an estimated PDUFA date of Sept. 29. Read more>>>
By Sam Fazeli, Bloomberg Industries Boehringer Ingelheim may join Novartis in challenging GlaxoSmithKline’s dominance in the treatment of respiratory diseases with new safety data on its Respimat device. While the data may not stave off generic competition for one of its top-selling drugs, Spiriva, it may allow Boehringer to develop a competitive combination therapy. [...]
by Elizabeth Krutoholow Roche may be able to overtake Otsuka in the race to market in geographic atrophy (GA), by leveraging a biomarker test for lampalizumab to structure a smaller pivotal trial, or to garner a breakthrough designation with the FDA, according to Bloomberg Industries. The company will update investors on plans later this [...]
by Andrew Berens, MD & Thomas Smith, Bloomberg Industries Amgen’s $10.4 billion purchase of Onyx demonstrates an appetite among biotech and pharma for companies with commercialized products and an oncology pipeline. Other oncology-focused biotechs with at least one commercialized product include Incyte, Seattle Genetics, Medivation and Ariad, each with a market value of $3 [...]
by Elizabeth Krutoholow Total knee replacement surgery is a cost-effective treatment and should not be restricted for appropriate patients by payers looking to save money as demand for the procedure increases, said Dr. Joshua Jacobs, president of the American Academy of Orthopaedic Surgeons. This rise in demand is driven by the fact that total knee [...]
by Elizabeth Krutoholow Arena’s Belviq and Vivus’ Qsymia have been readily adopted by weight loss experts, according to Dr. Ken Fujioka, director, Nutrition and Metabolic Research and of the Center for Weight Management at Scripps Clinic. Persistence of use, particularly among primary care doctors will be critical for the companies to maintain this [...]
by Elizabeth Krutoholow Biogen’s Tecfidera is unlikely to face competition from generic dimethyl fumarate, according to physicians interviewed. The company introduced its oral multiple sclerosis (MS) drug in the U.S. in the second quarter this year. In its recent earnings call, Biogen said the launch is “going very well.” Read More >>>
Bipartisan legislation in both chambers of Congress would strengthen the pharmaceutical supply chain by creating a single nationwide system of tracking prescription drugs from manufacturer to end user. A key question has thus far prevented enactment of a national supply chain standard: Should the specificity of such a tracking program be unit-level or lot-level? To read more, click here.